Table 3.
Multivariate logistic regression of included clinical variables for 3-month functional outcome and 1-month mortality in original cohort.
| 3-month functional outcome | OR | 95% CI | P-value |
|---|---|---|---|
| GCS (per 1-point increase) | 0.686 | 0.606–0.776 | <0.001 |
| Smoking (yes vs. no) | 1.426 | 0.791–2.572 | 0.238 |
| Hematoma volume (per 1-ml increase) | 1.022 | 1.002–1.042 | 0.027 |
| Hematoma location (supratentorial vs. infratentorial) | 2.452 | 1.100–5.467 | 0.028 |
| Presence of IVH (yes vs. no) | 1.272 | 0.496–3.263 | 0.616 |
| Presence of hematoma expansion (yes vs. no) | 1.093 | 0.508–2.351 | 0.820 |
| Treatment (surgical intervention vs. conservative treatment) | 2.455 | 1.044–5.773 | 0.040 |
| Neutrophil (per 1 × 109/L increase) | 1.080 | 0.981–1.189 | 0.118 |
| Lymphocyte (per 1 × 109/L increase) | 0.469 | 0.290–0.758 | 0.002 |
| Monocyte (per 1 × 109/L increase) | 28.642 | 4.427–185.296 | <0.001 |
| NLR (per 1-point increase) | 1.051 | 1.004–1.100 | 0.031 |
| SIRI (per 1-point increase) | 1.302 | 1.120–1.512 | 0.001 |
| 1-month mortality | |||
| GCS (per 1-point increase) | 0.700 | 0.637–0.769 | <0.001 |
| Duration from onset to hospitalization (per 1-h increase) | 0.987 | 0.962–1.013 | 0.328 |
| Hematoma volume (per 1-ml increase) | 1.012 | 1.000–1.025 | 0.046 |
| Hematoma location (supratentorial vs. infratentorial) | 0.529 | 0.221–1.267 | 0.153 |
| Presence of hematoma expansion (yes vs. no) | 1.504 | 0.756–2.992 | 0.245 |
| Neutrophil (per 1 × 109/L increase) | 1.019 | 0.940–1.105 | 0.646 |
| Monocyte (per 1 × 109/L increase) | 3.734 | 1.283–10.869 | 0.016 |
| NLR (per 1-point increase) | 1.021 | 0.987–1.057 | 0.225 |
| SIRI (per 1-point increase) | 1.072 | 1.020–1.126 | 0.006 |
OR, odds ratio; GCS, Glasgow Coma Scale; IVH, intraventricular hematoma; NLR, neutrophil-to-lymphocyte ratio; SIRI, systemic inflammation response index. Significant findings are expressed in bold and italic.